arXiv

Med-V1: Small Language Models for Zero-shot and Scalable Biomedical Evidence Attribution

Title: Med-V1: Lightweight Language Models Enable Scalable, Zero-Shot Biomedical Evidence Attribution

Verifying whether source material substantiates specific claims is a critical step in detecting hallucinations and validating assertions. Although large language models (LLMs) offer the capability to automate this verification process, achieving high performance typically necessitates the use of cutting-edge models like GPT-5. However, the prohibitive cost of deploying such frontier models at scale presents a significant barrier. To address this challenge in biomedical evidence attribution, we introduce Med-V1, a new family of small language models comprising just three billion parameters.

Developed using high-quality synthetic data created specifically for this research, Med-V1 demonstrates substantial improvements over its base models, with performance gains ranging from 27.0% to 71.3% across five biomedical benchmarks reformatted for verification tasks. Remarkably, despite its reduced size, Med-V1 delivers performance comparable to leading frontier LLMs, including GPT-5, while also providing high-quality explanations to support its predictions.

We leveraged Med-V1 for a pioneering use case study designed to quantify hallucinations in LLM-generated responses under varying citation instructions. The findings indicate that instruction formatting significantly influences both citation validity and hallucination rates. Notably, while GPT-5 produced a higher volume of claims, its hallucination rate remained similar to that of GPT-4o.

In a second application, we demonstrated that Med-V1 can automatically detect high-stakes evidence misattributions within clinical practice guidelines. This capability highlights potentially adverse public health impacts that are otherwise difficult to identify on a large scale. Ultimately, Med-V1 serves as an efficient, accurate, and lightweight alternative to expensive frontier LLMs, offering a practical solution for real-world biomedical evidence attribution and verification. Med-V1 is accessible at https://github.com/ncbi-nlp/Med-V1.


Source: arXiv Generated at: 2026-06-02 00:00:00 UTC

Related Articles

Advantech's Tsai on Nvidia Collaboration, AI Strategy
Bloomberg

Advantech's Tsai on Nvidia Collaboration, AI Strategy

Advantech's Tsai discusses the Nvidia partnership and AI strategy.

SK Hynix to Double Wafer Capacity to Ease Memory Chip Crunch
Bloomberg

SK Hynix to Double Wafer Capacity to Ease Memory Chip Crunch

SK Hynix plans to double its wafer capacity to alleviate the ongoing global memory chip shortage. This expansion aims to...

AI Productivity Boost Is Overhyped | 3-Minute MLIV
Bloomberg

AI Productivity Boost Is Overhyped | 3-Minute MLIV

The video argues that AI’s productivity boost is overhyped, challenging the assumption that it will significantly enhanc...

Intel's Lip-Bu Tan on Agentic AI & Partner Networks
Bloomberg

Intel's Lip-Bu Tan on Agentic AI & Partner Networks

Intel’s Lip-Bu Tan discusses Agentic AI and the vital role of partner networks in driving innovation.

Haas Says Arm May Hit $15 Billion AI Chip Revenue Goal Early
Bloomberg

Haas Says Arm May Hit $15 Billion AI Chip Revenue Goal Early

Haas suggests Arm may achieve its $15 billion AI chip revenue target sooner than expected. This indicates strong market ...

Arm May Hit $15 Billion AI Chip Revenue Goal Early, CEO Says
Bloomberg

Arm May Hit $15 Billion AI Chip Revenue Goal Early, CEO Says

Arm’s CEO predicts the company could hit its $15 billion AI chip revenue target ahead of schedule. This optimistic outlo...